Logotype for Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals (LXRX) Q3 2026 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Lexicon Pharmaceuticals Inc

Q3 2026 earnings summary

5 Nov, 2026

Executive summary

  • SONATA-HCM enrollment completed with 542 patients; topline results and a planned ZYNQUISTA NDA resubmission are both expected in Q1 2027.

  • Q3 revenue was $11.3M, including a third $10M Novo Nordisk milestone; 2026 milestone receipts totaled $30M as of Nov. 5.

  • Portfolio priorities include sotagliflozin for HCM and T1D, LX9851 in Novo Nordisk Phase 1 development, and pilavapadin for neuropathic pain and other indications.

Financial highlights

  • Q3 revenue was $11.3M vs. $14.2M in Q3 2025; 2026 revenue included a $10M Novo milestone and $1.2M in INPEFA net sales.

  • R&D expense was $16.2M vs. $18.8M, SG&A was $9.5M vs. $7.6M, and total operating expenses were $25.7M vs. $26.4M.

  • Net loss was $14.0M, or $0.03/share, vs. $12.8M, or $0.04/share; each period included $3.4M of non-cash stock-based compensation.

  • Nine-month revenue was $33.0M vs. $44.3M; net loss was $46.8M vs. $34.8M, and operating expenses were $75.1M vs. $78.4M.

Outlook and guidance

  • FY 2026 operating expense guidance remains $100M–$110M: R&D $63M–$68M and SG&A $37M–$42M; guidance excludes Phase 3 pilavapadin trial expenses.

  • SONATA-HCM topline results and ZYNQUISTA NDA resubmission are expected in Q1 2027; SOTA-CROSS nHCM study completion is expected in 1H 2027.

  • Current unrestricted cash and investment balances, plus expected collaboration and other revenue, are projected to fund planned operations for at least 12 months from the report date.

  • Further pilavapadin development depends on strategic collaboration or other financing; existing capital is insufficient for Phase 3 DPNP or broader neuropathic pain development.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Lexicon Pharmaceuticals